A New Licensed Quadrivalent Antileptospiral Canine Vaccine Prevents Mortality, Clinical Signs, Infection, Bacterial Excretion, Renal Carriage and Renal Lesions Caused by Australis Experimental Challenge.

Background: Australis is one of the most prevalent strains infecting dogs, leading, in natural conditions, to severe life-threatening cases.

Objective: The objective was to evaluate the onset and duration of immunity (OOI and DOI) induced by a new licensed quadrivalent antileptospiral vaccine (EURICAN L4) including four components (Canicola, Icterohaemorrhagiae, Grippotyphosa and Australis) against Australis. To this end, a severe Australis challenge model was developed, using a canine strain recently isolated from the field.